Allison Clemens
April
ababaabhay
achoi2392
adhoward1

2025 PACUPrep BCCCP Preparatory Course Acute Kidney Injury (AKI) Acute Kidney Injury: Foundations, Management, and Recovery

Lesson 15, Topic 1

In Progress

← Previous

Acute Kidney Injury: Foundations, Management, and Recovery

Lesson Progress

0% Complete

Foundational Principles of AKI: Epidemiology, Pathophysiology, and Risk Factors

Learning Objective

Describe the foundational principles of AKI, including its pathophysiology, clinical presentation, and risk factors.

1. Introduction to AKI

Acute kidney injury (AKI) is an abrupt decline in renal function—marked by rising serum creatinine and/or falling urine output—common in critically ill patients and linked to worse outcomes and higher resource use.

Definition: Increase in serum creatinine ≥0.3 mg/dL within 48 hours or ≥1.5× baseline within 7 days; urine output <0.5 mL/kg/h for ≥6 hours.
Significance: AKI complicates 20–50% of ICU admissions, doubles short‐ and long‐term mortality risk, prolongs ICU/hospital stay, and drives healthcare costs.

Clinical Pearl

AKI is a syndrome reflecting systemic illness severity; early identification of its type guides targeted interventions.

2. Epidemiology and Incidence

AKI incidence in ICU patients ranges from 30% to 60%, varying with patient population and diagnostic criteria; even mild AKI independently increases mortality and progression to CKD.

ICU prevalence: 30–60%; highest in sepsis, cardiac surgery, trauma cohorts.
Mortality impact: Two‐ to five‐fold increase; stage‐dependent: KDIGO stage 3 mortality >60%.
CKD progression: Dialysis‐requiring AKI markedly elevates risk of chronic dialysis.
Economic burden: AKI prolongs LOS by 3–5 days, doubles costs, increases RRT resource use.
Classification effect: RIFLE vs AKIN vs KDIGO yield different incidence rates; KDIGO most sensitive.

Table 1: Overview of AKI Classification Systems
System	Key Feature / Emphasis	General Sensitivity
RIFLE	Risk, Injury, Failure, Loss, ESRD (Severity-based stages)	Moderate
AKIN	Modification of RIFLE (Smaller SCr changes, 48h timeframe)	Higher than RIFLE
KDIGO	Unified definition (SCr & UO criteria), incorporates aspects of RIFLE/AKIN	Highest, Clinically Preferred

Clinical Pearl

Choice of AKI definition (RIFLE/AKIN/KDIGO) markedly alters reported incidence; KDIGO is preferred for consistency and prognostication.

3. Key Pathophysiological Mechanisms

AKI arises from intertwined ischemic, nephrotoxic, and inflammatory pathways leading to tubular injury, endothelial dysfunction, and maladaptive repair.

Ischemic Injury

(Hypoperfusion, Microvascular)

Nephrotoxic Injury

(Drugs, Contrast, Toxins)

Inflammatory Injury

(Sepsis, Cytokines)

Acute Kidney Injury (AKI)

Tubular Injury, Endothelial Dysfunction, Maladaptive Repair

Figure 1: Key Pathophysiological Pillars Leading to Acute Kidney Injury.

A. Ischemic Injury

Renal hypoperfusion from hypotension, shock, or impaired autoregulation.
Microvascular dysfunction: endothelial activation, leukocyte adhesion, microthrombi.
Tubular cell apoptosis/necrosis and decreased GFR.

B. Nephrotoxic Injury

Direct tubular epithelial toxicity (e.g., aminoglycosides, cisplatin, contrast media).
Oxidative stress and mitochondrial dysfunction impair ATP generation.
Synergy with volume depletion and pre‐existing CKD amplifies injury.

C. Inflammatory Injury

Cytokine surge (e.g., TNF-α, IL-6) in sepsis triggers tubular damage.
Leukocyte infiltration and complement activation worsen microcirculatory flow.
Sepsis‐associated AKI often occurs despite maintained or increased renal blood flow.

D. Cellular and Molecular Responses

Tubular cell cycle arrest (G2/M) promotes fibrotic transition.
Free radical formation and mitochondrial injury perpetuate damage.
Novel biomarkers (e.g., NGAL, KIM-1, TIMP-2*IGFBP7, suPAR) detect early tubular stress.

Clinical Pearl

Sepsis‐induced AKI is a complex interplay of inflammation, endothelial injury, and metabolic reprogramming—not simply ‘‘low flow’’.

4. Clinical Presentation and Diagnostics

AKI may present with oliguria/anuria or remain non‐oliguric; diagnosis relies on trend monitoring of creatinine, urine output, and adjunctive tests.

Clinical signs: Oliguria (<0.5 mL/kg/h), edema, pulmonary crackles, hypertension.
Laboratory: Rising serum creatinine and BUN; fractional excretion of sodium (FENa) aids pre‐renal vs intrinsic differentiation.
Urinalysis: Granular casts, tubular epithelial cells, proteinuria patterns.
Imaging/tests: Renal ultrasound to exclude obstruction; Doppler for perfusion; emerging biomarkers for early detection.

Table 2: Key Diagnostic Clues in AKI Evaluation
Test / Finding	Interpretation in AKI Context	Notes
Serum Creatinine (SCr)	Rising trend indicates declining GFR	Baseline needed; changes lag actual injury.
Urine Output (UO)	Oliguria (<0.5 mL/kg/h) or Anuria	Non-oliguric AKI is common; monitor hourly.
FENa (Fractional Excretion of Sodium)	<1% suggests prerenal azotemia; >2% suggests intrinsic ATN	Less reliable with diuretic use; FEUrea may be alternative.
Urinalysis: Granular Casts	Suggestive of Acute Tubular Necrosis (ATN)	Often described as “muddy brown” casts.
Urinalysis: Tubular Epithelial Cells	Indicate direct tubular damage	May be seen with casts.
Renal Ultrasound	Rules out postrenal obstruction	Can also assess kidney size (chronicity).

Clinical Pearl

Non‐oliguric AKI is common—monitor urine output continuously and interpret creatinine trends in context of fluid shifts.

5. Influence of Chronic Comorbidities

Baseline CKD, diabetes, and heart failure amplify AKI risk by reducing reserve, altering microvasculature, and promoting congestion.

CKD: Even mild GFR reduction predisposes to severe, non‐reversible AKI and progression to ESRD.
Diabetes: Microvascular injury and chronic inflammation heighten susceptibility to nephrotoxins and ischemia.
Heart failure (cardiorenal syndrome): Renal venous congestion and neurohormonal activation drive AKI despite adequate arterial flow.

Clinical Pearl

Patients with acute on chronic kidney disease or cardiorenal syndrome have the highest AKI mortality—target aggressive prevention and early recognition.

6. Social Determinants of Health and Outcomes

Socioeconomic status, health literacy, and medication access critically influence AKI recognition, prevention, and recovery.

Medication access: Delays or interruptions in crucial therapies (e.g., antihypertensives) increase AKI risk.
Health literacy: Poor understanding of nephrotoxins and fluid management delays presentation.
Socioeconomic factors: Transportation barriers and insurance status affect follow‐up and long‐term outcomes.

Clinical Pearl

Pharmacists can mitigate disparities by ensuring medication affordability, clear education, and coordination of outpatient follow‐up.

7. Clinical Risk Stratification and Application

Combine clinical scores, biomarkers, and pharmacist‐led stewardship for proactive AKI risk management and prevention bundles.

Risk tools: SOFA, APACHE II provide baseline severity context.
Biomarkers: TIMP-2*IGFBP7 and NGAL identify subclinical AKI and high‐risk patients.
Pharmacist interventions: Nephrotoxin avoidance, dose adjustments, medication reconciliation.
Bundled care: Protocolized hemodynamic optimization and biomarker‐guided KDIGO bundle reduce perioperative AKI.

Table 3: Components of AKI Risk Stratification and Prevention
Component Type	Examples	Role in AKI Management
Clinical Risk Scores	SOFA, APACHE II, specific AKI risk models	Assess baseline illness severity, predict general AKI risk.
Novel Biomarkers	TIMP-2*IGFBP7 (NephroCheck®), NGAL, KIM-1, [TIMP-2]•[IGFBP7]	Detect early kidney stress/injury before SCr rise, identify high-risk patients.
Pharmacist-led Interventions	Nephrotoxin review & avoidance, Dose adjustments for renal function, Medication reconciliation	Prevent/mitigate drug-induced AKI, optimize therapy during AKI.
Bundled Care Approaches	KDIGO-based care bundles, Perioperative AKI prevention protocols, Sepsis bundles	Standardize care, improve adherence to preventative measures, timely interventions.

Clinical Pearl

Integrate risk scoring with early biomarkers and targeted pharmacist‐led bundles to shift from reactive to proactive AKI care.

References

Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure—Definition, outcome measures, fluid therapy: The ADQI consensus. Crit Care. 2004;8(4):R204–R212.
Chertow GM, Burdick E, Honour M, et al. AKI, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365–3370.
Gomez H, Ince C, De Backer D, et al. A unified theory of sepsis‐induced AKI. Shock. 2014;41(1):3–11.
Hayek SS, Leaf DE, Samman Tahhan A, et al. suPAR and AKI. N Engl J Med. 2020;382(5):416–426.
Hsu CY, Chertow GM, McCulloch CE, et al. Nonrecovery of kidney function after acute on chronic renal failure. Clin J Am Soc Nephrol. 2009;4(5):891–898.
Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of AKI in ICU patients: the AKI‐EPI study. Intensive Care Med. 2015;41(8):1411–1423.
Kashani K, Al‐Khafaji A, Ardiles T, et al. Discovery of cell cycle arrest biomarkers in human AKI. Crit Care. 2013;17(1):R25.
Khwaja A; KDIGO AKI Work Group. KDIGO clinical practice guideline for AKI. Nephron Clin Pract. 2012;120(4):c179–c184.
KDIGO. Scope of Work: KDIGO guideline update on AKI and AKD. 2023.
Lo LJ, Go AS, Chertow GM, et al. Dialysis‐requiring ARF increases CKD risk. Kidney Int. 2009;76(8):893–899.
Mehta RL, Kellum JA, Shah SV, et al. AKIN: report to improve AKI outcomes. Crit Care. 2007;11(2):R31.
Pickkers P, Darmon M, Hoste E, et al. AKI in the critically ill: pathophysiology and management. Intensive Care Med. 2021;47(8):835–850.
Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: AHA statement. Circulation. 2019;139(16):e840–e878.

2025 PACUPrep BCCCP Preparatory Course

Pulmonary

Participants 432

Acute Kidney Injury: Foundations, Management, and Recovery

Foundational Principles of AKI: Epidemiology, Pathophysiology, and Risk Factors

Learning Objective

1. Introduction to AKI

2. Epidemiology and Incidence

3. Key Pathophysiological Mechanisms

A. Ischemic Injury

B. Nephrotoxic Injury

C. Inflammatory Injury

D. Cellular and Molecular Responses

4. Clinical Presentation and Diagnostics

5. Influence of Chronic Comorbidities

6. Social Determinants of Health and Outcomes

7. Clinical Risk Stratification and Application

References